Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Ovarian Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 113 Carboplatin 99 Bevacizumab 59 pembrolizumab 56 liposomal doxorubicin 56 Gemcitabine 42 olaparib 39 Topotecan 33 niraparib 29 Nivolumab 21 Cisplatin 21 Doxorubicin 17 Cyclophosphamide 17 1-dodecylpyridoxal 16 Drug Therapy 15 Docetaxel 15 avelumab 13 Fulvestrant 11 oregovomab 10 Oxaliplatin 10 rucaparib 9 fludarabine 9 Injections 9 Fluorouracil 9 veliparib 8 mirvetuximab soravtansine 8 atezolizumab 8 Cetuximab 8 fluzoparib 7 cemiplimab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × guadecitabine × Clear all

NCT01696032 2024-08-27

SGI-110

Astex Pharmaceuticals, Inc.

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡